Mood stabilizers in psychiatric disorders and mechanisms learnt from in vitro model systems

By: Nayak R., Rosh I., Kustanovich I., Stern S.
Published in: International Journal of Molecular Sciences
SDGs : SDG 03  |  Units: Natural Sciences  | Time: 2021 |  Link
Description: Bipolar disorder (BD) and schizophrenia are psychiatric disorders that manifest unusual mental, behavioral, and emotiona l patterns leading to suffering and disability. These disorders span heterogeneous conditions with variable heredity and elusive pathophysiology. Mood stabilizers such as lithium and valproic acid (VPA) have been shown to be effective in BD and, to some extent in schizophrenia. This review highlights the efficacy of lithium and VPA treatment in several ran-domized, controlled human trials conducted in patients suffering from BD and schizophrenia. Fur-thermore, we also address the importance of using induced pluripotent stem cells (iPSCs) as a disease model for mirroring the disease’s phenotypes. In BD, iPSC-derived neurons enabled finding an endophenotype of hyperexcitability with increased hyperpolarizations. Some of the disease phe-notypes were significantly alleviated by lithium treatment. VPA studies have also reported rescuing the Wnt/β-catenin pathway and reducing activity. Another significant contribution of iPSC models can be attributed to studying the molecular etiologies of schizophrenia such as abnormal differentiation of patient-derived neural stem cells, decreased neuronal connectivity and neurite number, impaired synaptic function, and altered gene expression patterns. Overall, despite significant ad-vances using these novel models, much more work remains to fully understand the mechanisms by which these disorders affect the patients’ brains. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.